



Anja Harder

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Anja Harder
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 1094
Anja.Harder@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

study nurse

Publications (0)

No results found.

Projects (16)

ETOP 25-23 ADOPT-lung

Clinical Studies - Dec 6, 2024 - Dec 31, 2029

Ongoing

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) (Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)

Clinical Studies - Aug 13, 2024 - Dec 31, 2099

Ongoing

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Clinical Studies - Nov 3, 2023 - Dec 31, 2099

Ongoing

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

Clinical Studies - Oct 18, 2023 - Dec 31, 2099

Ongoing

A PHASE IB/II RANDOMIZED, OPEN LABEL DRUG REPURPOSING TRIAL OF GLUTAMATE SIGNALING INHIBITORS IN COMBINATION WITH CHEMORADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GLUGLIO)

Clinical Studies - May 10, 2023 - Dec 31, 2030

Ongoing

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Clinical Studies - Mar 14, 2023 - Dec 31, 2099

Ongoing

CA209-6K7 - Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti-CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study

Clinical Studies - Dec 9, 2022 - Dec 31, 2099

Ongoing

A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL)

Clinical Studies - Dec 16, 2021 - Dec 31, 2099

Ongoing

DS1062-A-U303 (TROPION-lung07) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations TROPION-Lung07

Clinical Studies - Oct 8, 2021 - Dec 31, 2099

Ongoing

Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial

Clinical Studies - Jun 8, 2021 - Dec 31, 2099

Ongoing

Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT Trial

Clinical Studies - Mar 4, 2021 - Dec 31, 2099

Ongoing

IPSEN F-FR-60000-023

Clinical Studies - Jul 17, 2020 - Dec 31, 2099

Ongoing

A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line. MITO-16b, MANGO-OV2b

Clinical Studies - Jul 9, 2020 - Jun 21, 2023

Completed

Open-label, non-randomized phase-1 study of liposomal doxorubicin TLD-1 in patients with advanced solid tumors

Clinical Studies - Oct 26, 2018 - Dec 22, 2023

Completed

ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial

Clinical Studies - Mar 31, 2017 - Jun 6, 2024

Completed

SAKK HOVON 135

Clinical Studies - Oct 27, 2016 - Dec 31, 2019

Ongoing

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch